About the Authors

Alexander Pretsch

Contributed equally to this work with: Alexander Pretsch, Michael Nagl

Affiliation SeaLife Pharma GmbH, Tulln, Austria

Michael Nagl

Contributed equally to this work with: Alexander Pretsch, Michael Nagl

Affiliation SeaLife Pharma GmbH, Tulln, Austria

Katja Schwendinger

Affiliation SeaLife Pharma GmbH, Tulln, Austria

Birgit Kreiseder

Affiliation SeaLife Pharma GmbH, Tulln, Austria

Martina Wiederstein

Affiliation SeaLife Pharma GmbH, Tulln, Austria

Dagmar Pretsch

Affiliation SeaLife Pharma GmbH, Tulln, Austria

Miroslav Genov

Affiliation SeaLife Pharma GmbH, Tulln, Austria

Ralph Hollaus

Affiliation SeaLife Pharma GmbH, Tulln, Austria

Daniela Zinssmeister

Affiliation SeaLife Pharma GmbH, Tulln, Austria

Abdesamad Debbab

Affiliation Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University, Düsseldorf, Germany

Harald Hundsberger

Affiliation Medical and Pharmaceutical Biotechnology, University of Applied Sciences, Krems, Austria

Andreas Eger

Affiliation Medical and Pharmaceutical Biotechnology, University of Applied Sciences, Krems, Austria

Peter Proksch

Affiliation Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University, Düsseldorf, Germany

Christoph Wiesner

wiesner@sealifepharma.com

Affiliation SeaLife Pharma GmbH, Tulln, Austria

Competing Interests

SeaLife Pharma GmbH holds the patent for the Anthracene derivatives (“Neue Tetrahydroanthracenon-Derivate”; WO 2010135758 A1; compound AA ´) isolated from T. wortmannii. A. Pretsch, P. Proksch, and A. Debbab are the inventors of the patent and SeaLife Pharma GmbH is the patent holder. In the next two years, SeaLife GmbH plans to market and commercialize the T. wortmannii extract as a cosmetic product. A. Pretsch (Head of Microbiology and CEO), M. Nagl (Head of Chemistry), K. Schwendinger (Master Student), B. Kreiseder (Junior Scientist), M. Wiederstein (Junior Scientist), D. Pretsch (Junior Scientist), D. Zinssmeister (Master Student), M. Genov (Senior Scientist), R. Hollaus (Junior Scientist), and C. Wiesner (CSO) are all employed at SeaLife Pharma GmbH. Beside the product above, SeaLife Pharma GmbH is developing (pre-clinical studies) an anti-infective Anthraquinone-Derivative (patent in preparation) for the treatment of MRSA. Up to now, SeaLife Pharma has no products on the market. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: AP CW. Performed the experiments: AP MN KS BK MW DP RH DZ HH CW. Analyzed the data: AP MG CW. Contributed reagents/materials/analysis tools: AD HH AE PP. Wrote the paper: MN CW.